Baldwin Wealth Partners LLC MA Has $15.71 Million Holdings in Danaher Corporation $DHR

Baldwin Wealth Partners LLC MA lessened its holdings in Danaher Corporation (NYSE:DHR) by 4.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 79,237 shares of the conglomerate’s stock after selling 3,267 shares during the quarter. Danaher makes up approximately 1.0% of Baldwin Wealth Partners LLC MA’s holdings, making the stock its 23rd biggest holding. Baldwin Wealth Partners LLC MA’s holdings in Danaher were worth $15,710,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Hall Laurie J Trustee boosted its stake in Danaher by 2.1% in the third quarter. Hall Laurie J Trustee now owns 22,559 shares of the conglomerate’s stock valued at $4,473,000 after acquiring an additional 465 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Danaher by 12.3% in the 3rd quarter. Brighton Jones LLC now owns 11,671 shares of the conglomerate’s stock valued at $2,314,000 after purchasing an additional 1,281 shares during the period. DLK Investment Management LLC boosted its position in shares of Danaher by 0.5% in the 3rd quarter. DLK Investment Management LLC now owns 25,031 shares of the conglomerate’s stock worth $4,963,000 after purchasing an additional 127 shares during the last quarter. TCI Wealth Advisors Inc. boosted its position in shares of Danaher by 3.4% in the 3rd quarter. TCI Wealth Advisors Inc. now owns 2,415 shares of the conglomerate’s stock worth $479,000 after purchasing an additional 80 shares during the last quarter. Finally, Foster Victor Wealth Advisors LLC grew its stake in shares of Danaher by 15.6% during the third quarter. Foster Victor Wealth Advisors LLC now owns 91,656 shares of the conglomerate’s stock worth $19,705,000 after purchasing an additional 12,376 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 30,248 shares of company stock worth $6,609,663. 11.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent analyst reports. Barclays raised their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Morgan Stanley assumed coverage on shares of Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 price target on the stock. TD Cowen boosted their price objective on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a research note on Thursday. Finally, Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $248.25.

Danaher Stock Up 0.2%

Shares of DHR stock opened at $224.78 on Monday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average of $220.37 and a 200-day moving average of $207.11. The company has a market capitalization of $158.77 billion, a price-to-earnings ratio of 46.35, a P/E/G ratio of 4.36 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.71 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio is currently 26.39%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.